Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foundation Adds New Markers To FoundationOne Cancer Testing Platform

Executive Summary

US FDA and the Centers for Medicare and Medicaid Services have already accepted FoundationOne for Parallel Review and Expedited Access for breakthrough devices. The new markers will help identify patients best-suited to immunotherapy or other targeted therarapies, the company says.


Related Content

Precision Medicine: Despite Gains, Optimum Use Far From Reached
Multi-Companion Profiling Assay Enters FDA, CMS Express Lanes
INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts